Table 1.
Demographic, laboratory, and medical data for all subjects.
| N | Age | Sex | Dg | CYP3A4 | CYP3A5 | CYP2J2 | MDR1/ABCB1 |
ABCG2/ BCRP |
RIVA Adverse Event (Bleeding) |
RIVA DD (mg) |
eGFR (mL/min /1.73 m2) |
DDI RR/DDI |
DDI Bleeding Risk/RIVA Conc. |
|||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| *1B | *22 | *3 | *7 | rs 11572325 |
c.1236C>T rs 1128503 |
c.2677G>T rs 2032582 |
c.3435C>T rs 1045642 |
rs 4148738 |
c.421C>A | |||||||||
| 1 | 68 | M | AF | *1/*1 | *1/*1 | *3/*3 | *1/*1 | A/A | C/C | G/G | C/C | G/G | C/C | GI | 20 | 88 | - | - |
| 2 | 80 | F | AF | *1/*1 | *1/*1 | *3/*3 | *1/*1 | A/A | T/T | T/T | T/T | A/A | C/A | GI | 15 | 38 | C./RIVA-duloxetine D./RIVA-clopidogrel |
Bleeding risk may be increased |
| 3 | 64 | M | AF | *1/*1 | *1/*1 | *3/*3 | *1/*1 | A/A | C/C | G/G | C/C | G/G | C/C | GI | 20 | 100 | - | - |
| 4 | 75 | M | AF | *1/*1 | *1/*1 | *3/*3 | *1/*1 | A/A | C/T | G/T | C/T | G/A | C/C | GI | 20 | 43 | D./RIVA-indomethacin | Bleeding risk may be increased |
| 5 | 66 | M | AF | *1/*1 | *1/*1 | *1/*3 | *1/*1 | A/A | C/T | G/T | C/T | G/A | C/C | Haematuria | 15 | 89 | B./RIVA-propafenone | P-gp/ABCB1 inhibitors may increase the serum RIVA conc. |
| 6 | 66 | F | AF | *1/*1 | *1/*1 | *3/*3 | *1/*1 | A/A | C/C | G/G | C/C | G/G | C/C | Epistaxis | 20 | 105 | - | - |
| 7 | 75 | F | AF | *1/*1 | *1/*1 | *1/*3 | *1/*7 | A/T | C/T | G/T | C/T | G/A | C/C | Epistaxis | 15 | 35 | D./RIVA-ASA D./RIVA-ketoprofen |
Bleeding risk may be increased |
| 8 | 72 | F | AF | *1/*1 | *1/*1 | *1/*3 | *1/*7 | A/T | C/C | G/G | C/C | G/G | C/A | Epistaxis | 20 | 88 | - | - |
| 9 | 75 | M | AF | *1/*1 | *1/*1 | *3/*3 | *1/*1 | A/T | C/T | G/T | C/T | G/A | C/C | GI | 15 | 54 | B./RIVA-amiodarone | P-gp/ABCB1 inhibitors may increase the serum RIVA conc. |
| 10 | 76 | F | DVT | *1/*1 | *1/*1 | *3/*3 | *1/*1 | A/A | C/C | G/G | C/C | G/G | C/A | GI | 15 | 34 | - | - |
| 11 | 61 | F | DVT | *1/*1 | *22/*22 | *3/*3 | *1/*7 | A/T | C/T | G/T | C/T | G/A | C/C | Gynaecological | 10 | 85 | D./RIVA-ASA | Bleeding risk may be increased |
| 12 | 75 | F | AF | *1/*1 | *1/*1 | *3/*3 | *1/*1 | A/T | C/T | G/T | C/T | G/A | C/C | GI | 15 | 61 | B./RIVA-amiodarone D./RIVA-clopidogrel |
P-gp/ABCB1 inhibitors may increase the serum RIVA conc. Bleeding risk may be increased |
| 13 | 78 | M | PAD | *1/*1 | *1/*1 | *3/*3 | *1/*7 | A/T | T/T | T/T | T/T | A/A | C/C | Epistaxis | 5 | 70 | D./RIVA-ASA | Bleeding risk may be increased |
| 14 | 74 | F | PAD | *1/*1 | *1/*1 | *3/*3 | *1/*1 | A/A | C/T | G/G | C/T | G/G | C/C | GI | 20 | 48 | B./RIVA-amiodarone | P-gp/ABCB1 inhibitors may increase the serum RIVA conc. |
| 15 | 69 | F | AF | *1/*1 | *1/*1 | *3/*3 | *1/*1 | A/A | C/T | G/T | C/T | G/A | C/C | Epistaxis | 20 | 82 | - | - |
| 16 | 66 | M | AF | *1/*1 | *1/*22 | *3/*3 | *1/*1 | A/A | C/C | G/G | C/C | G/A | A/A | GI | 20 | 63 | - | - |
AF atrial fibrillation; ASA acetylsalicylic acid; DD daily dose; DDI drug–drug interaction; DVT deep vein thrombosis; eGFR estimated glomerular filtration rate; GI gastrointestinal; PAD peripheral arterial disease; RIVA rivaroxaban; RR risk rating from Lexicomp (B No action needed; C Monitor therapy; D Consider therapy modification). Minor and variant pharmacogenes alleles and decreased eGFR values are in bold.